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Chromosomal structural variations play an important role in determining the transcriptional landscape of human breast
cancers. To assess the nature of these structural variations, we analyzed eight breast tumor samples with a focus on regions
of gene amplification using mate-pair sequencing of long-insert genomic DNA with matched transcriptome profiling. We
found that tandem duplications appear to be early events in tumor evolution, especially in the genesis of amplicons. In
a detailed reconstruction of events on chromosome 17, we found large unpaired inversions and deletions connect a tan-
demly duplicated ERBB2 with neighboring 17q21.3 amplicons while simultaneously deleting the intervening BRCA1 tumor
suppressor locus. This series of events appeared to be unusually common when examined in larger genomic data sets of
breast cancers albeit using approaches with lesser resolution. Using siRNAs in breast cancer cell lines, we showed that the
17q21.3 amplicon harbored a significant number of weak oncogenes that appeared consistently coamplified in primary
tumors. Down-regulation of BRCA1 expression augmented the cell proliferation in ERBB2-transfected human normal
mammary epithelial cells. Coamplification of other functionally tested oncogenic elements in other breast tumors ex-
amined, such as RIPK2 and MYC on chromosome 8, also parallel these findings. Our analyses suggest that structural vari-
ations efficiently orchestrate the gain and loss of cancer gene cassettes that engage many oncogenic pathways
simultaneously and that such oncogenic cassettes are favored during the evolution of a cancer.
[Supplemental material is available for this article.]
Cancer arises from normal cells progressively accumulating both
genetic and epigenetic changes that circumvent cellular regulatory
controls (Hanahan and Weinberg 2011). Genetic changes repre-
sent the ‘‘hard-wiring’’ of a cancer resulting in a genomic config-
uration that provides an evolutionary advantage for tumor growth
in the patient. Genetic changes through somatic mutations span
from single nucleotide alterations to breakpoints interrupting gene
contiguity, segmental copy number changes, and imbalances of
entire chromosomes. The spectrum of point mutations and small
insertions/deletions in breast cancers has been extensively studied
and revealed a limited number of genes that are frequently
mutated, such as TP53, PIK3CA, KRAS, and a larger number of
rare mutations with many of unclear importance (Banerji et al.
2012; The Cancer Genome Atlas Network 2012; Shah et al. 2012;
Stephens et al. 2012). The frequency of copy number gain and
loss and their relationship with patient prognosis have also been
examined in breast cancer (Chin et al. 2006; Hicks et al. 2006;
Beroukhim et al. 2010; J€onsson et al. 2010; Russnes et al. 2010;
Staaf et al. 2010; Curtis et al. 2012). Although in earlier studies the
major focus was to find specific driver oncogenes in amplicons
and tumor suppressor genes in common regions of loss (primarily
using loss of heterozygositymapping), progressively there emerged
an understanding that more than one driver oncogene may be
present in any amplicon. Moreover, each amplicon or region of
copy number loss alters the expression of many adjacent genes,
some with proven conjoint cancer effects (Zhang et al. 2009;
Curtis et al. 2012). Thus, any cancer is likely to be a composite of
hundreds to thousands of gene changes that contribute to the
cancer state. Although specific point mutations contribute to
adaptive evolutionary processes, recent genomic analyses from
controlled evolutionary experiments in model systems suggest
that copy number changes through segmental duplications and
rearrangements may play a more prominent role (Chang et al.
2013; Fares et al. 2013).
Previously, we investigated the transcriptional consequences
of somatic structural variations in primary breast cancers and cell
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lines (Hillmer et al. 2011; Inaki et al. 2011). Our observations
showed that in one amplified locus, a single tandem duplication
led to the selection of cancers with augmented expression of two
adjacent oncogenic components. Generalizing from this observa-
tion, we hypothesize that conjoint expression of adjacent onco-
genes or loss of adjacent cancer suppressors may provide a ‘‘systems
genetic’’ strategy for activating cassettes of oncogenic signals.
Herein, we seek to assess the importance of these structural varia-
tions in the establishment of a transcriptional state that might be
optimal for the evolution of an individual cancer.
Results
Genomic organization and its transcriptional consequences
in a set of breast tumors
To investigate recurrent molecular paths to breast oncogenesis,
we carried out whole-genome sequencing of ;10-kbp insert size–
mate pair libraries generated from the DNA of eight breast tumor
samples and their normal counterparts, representing different
breast cancer molecular subtypes (Supplemental Table 1). Because
we were interested in the dynamics of clinically relevant amplicon
formation, five of the eight tumors had histologic evidence for
ERBB2 amplification. The large insert size provided a significant
depth of coverage (1703 average physical coverage across the
16 sequenced genomes) (Supplemental Table 2) for the sensitive
detection of genomic structural variations. We complemented the
genomic data with transcriptomic information generated by either
RNA sequencing or microarray (Supplemental Tables 2, 3). Circos
plots representing somatic structural variations and copy number
changes are shown in Supplemental Figure 1.
On average, 22.1% of each haploid cancer genome appeared
to be affected by a focal change in copy number (from 1.9% to
43.1%) (Supplemental Methods), indicating that copy number
variations are major contributors to the somatic changes in the
genomic landscape of the analyzed breast tumors.
We confirmed previous evidence that copy number changes
substantially affect the transcriptional output of cancer genomes
(Curtis et al. 2012) by testing the expression dynamics of regions of
copy number loss and gain: In each of the eight individual tran-
scriptomes examined, genes affected by an increase in copy
number were generally expressed at high absolute levels, whereas
genes affected by a decrease in copy number were skewed toward
the low expression range (Supplemental Fig. 2).
Structural variations and fusion genes
To gain insight into the biological relevance of specific patterns of
copy number alterations, we focused on the functional genomic
consequences of structural variations, which are likely to initiate
massive copy number changes. Because the mate-pair sequencing
method is able to detect all forms of structural variations quanti-
tatively andwithhigh sensitivity (Hillmer et al. 2011; Inaki and Liu
2012), we examined the rearrangements of each tumor in detail
following the subtraction of its germline structural variations
(Supplemental Methods).
Each tumor exhibited proclivity for specific kinds of somatic
structural variations. For example, 74% of structural variations in
BT122, which is a triple negative breast cancer, are tandem dupli-
cations scattered across entire chromosomal regions (Supplemen-
tal Fig. 3; Supplemental Table 4). A similar configuration has been
recently described as the tandem duplicator phenotype (Ng et al.
2012). We also observed evidence of chromothripsis, another type
of genome-scale structural pattern (Stephens et al. 2011), on
chromosome 22 in BT55 (Supplemental Fig. 1), which appears as
a large number of clustered rearrangements associatedwith frequent
oscillation between two discrete copy number states. As an example
of the high-resolution structural details afforded by the mate-pair
sequencing approach, we detected an inversion at the 17p13.1 locus,
which truncated the TP53 gene body in BT122 and was associated
with low expression of the gene (Supplemental Fig. 4A). In BT73, an
unpaired inversion juxtaposed the promoter of a highly expressed
gene, EIF3H (734.4 FPKM), next toMYC, whichwas overexpressed in
this sample (114.7 FPKM) (Supplemental Fig. 4B).
Previous observations from our group suggested that somatic
structural variations most frequently affect gene structures (Inaki
et al. 2011). By cataloging fusion genes and gene truncations (fu-
sion gene, 39 truncation, 59 truncation, and intragenic rearrange-
ment) caused by structural variations in four of the sequenced
breast cancers, we confirmed that nearly 60% of somatic structural
variations affect gene structures (Supplemental Table 5). We tested
61 predicted gene fusions by RT-PCR and found that 37 of them
(61%) were expressed (Supplemental Table 6). Of these, only eight
fusion transcripts are in-frame and possess intact protein func-
tional domains, although none are recurrent fusions, and the fu-
sion partners have little plausible involvement in cancer, so that
their functional consequences remain unknown. These findings
are consistent with our previously published observations, which
noted such fusion events that do not directly create a functional
oncogene through the fusion but are indicative of a genomic
process that initiates more critical downstream oncogenic muta-
tions (Inaki et al. 2011; Inaki and Liu 2012).
Tandem duplications can function as initiators of gene
amplification
We previously reported that genes mapping to tandem duplica-
tions’ breakpoints are generally expressed at high levels (Inaki et al.
2011). Another possible oncogenic function of such segmental
duplications is the consequent increased gene expression of the
oncogenes they span. Indeed, we observed a 1.74-fold increase
in the expression level of genes mapping inside compared to out-
side tandem duplications in the breast cancers analyzed herein
(P-value < 1.00 3 104) (Fig. 1A).
We previously noted that tandem duplications appear fre-
quently in regions of higher segmental genomic amplification and
speculated that they may be integral to the formation of an
amplicon (Hillmer et al. 2011). We used the cluster size of the
structural variations, which is the number of discordantly mapped
mate-pair reads corresponding to a given structural variation, as
ameasure of the prevalence of themutated allele within the tumor
cell population and therefore, as an indication of the probable
chronological sequence by which different somatic rearrange-
ments occurred in the cancer genome. This allowed us to estimate
the genealogy of amplifications in the breast tumors examined.
Five of the eight breast tumors we analyzed (BT47, BT55,
BT58, BT146, and BT191) displayed evident gene amplification
(24, 14, 7, 26, and 22 copies, respectively) with associated high
levels of expression of the ERBB2 gene on chromosome 17 (Chr 17)
(Supplemental Table 1). In four of these tumors, we found tandem
duplications spanning the ERBB2 locus and surrounding its
amplicon; and in at least three cases, these events were associated
with locally high cluster sizes (cluster sizes 207 in BT55; 359, 377,
and 426 in BT146; and 45 in BT47) (Fig. 1B; Supplemental Fig. 5).
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Figure 1. Tandem duplications are involved in amplicon formation in breast cancer. (A) Density plot of expression values of genes located inside and
outside tandem duplications (TD) for the four breast tumors for which RNA-seq data is available. A P-value was computed based on 10,000 random gene
permutations. (B, upper) frequency of copy number gain around the ERBB2 locus on Chr 17 across a data set of 1174 breast cancers; (lower) genomic
coordinates corresponding to tandem duplications spanning the ERBB2 locus identified in nine different breast cancer samples. (C ) Amplified oncogenes
are significantly enriched for genes that are recurrently spanned by tandem duplications. Bars correspond to the fold enrichment compared to the all-gene
population, with error bars indicating the 95% confidence interval. (NS) Not significant; (*) average and standard deviation values based on 100 gene
permutations.
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This suggests that a tandem duplication affecting the ERBB2 gene
may occur as an early event during ERBB2 amplicon formation.
Similarly, we observed tandem duplications spanning ERBB2 in
other samples—two ERBB2-positive tumors (PD3693a and PD3670a)
and one triple negative breast cancer cell line (HCC38)—which
have been independently sequenced at a lower physical coverage
(Fig. 2B; Stephens et al. 2009). In BT71 and BT73, although no
overt ERBB2 amplification was clinically reported (Supplemental
Fig. 1), we found evidence of a moderate copy number increase
at the ERBB2 locus (;3 gene copies), indicative of an early stage
of amplicon formation. In both tumors, the ERBB2 locus was
spanned by a large tandem duplication (cluster size 141 in BT71
and 44 in BT73) (Fig. 2B; Supplemental Fig. 5).
Consistent with these results, when looking at the CDK4-
amplified tumor sample BT122, we found that one of the first so-
matic rearrangements to take place on chromosome 12p is a large
tandem duplication encompassing the CDK4 locus and preceding
a series of unpaired inversions and additional tandem duplica-
tions (Supplemental Results; Supplemental Fig. 6). Based on these
observations, we hypothesize that one of the functional conse-
quences of tandem duplications may be to nucleate and shape
oncogenic amplicons.
If tandem duplications are indeed often involved in the ear-
liest stages of amplicon formation, we would expect to find genes
frequently amplified in cancer to bemore often affected by tandem
duplications than other functionally relevant sets of genes. We
generated a list of genes that are most commonly affected by
tandem duplications based on a catalog of 96 breast cancer ge-
nomes (Supplemental Methods) and calculated the level of en-
richment for specific kinds of cancer-associated genes.Whereas no
significant association was observed between genes in tandem
duplications with oncogenes activated solely by somatic inter-
chromosomal translocation or pointmutation, a significant 4.4-fold
enrichment was found in tandem duplications for oncogenes that
are activated by focal amplifications (P-value = 6.673 109)
(Fig. 1C). This is further support for amodel of amplicon formation
in which a single tandemduplication spanning an oncogene is the
initiating event in a series of structural rearrangements, which
eventually generate additional copies of an oncogenic locus.
Coordinated rearrangement of Chr 17 structure in breast
cancer
In three cases (BT47, BT55, and BT146) with highly discernable
ERBB2 gene amplification, the copy number assessment suggested
that a sharp peak of amplification at the ERBB2 locus was immedi-
ately adjacent to a region of copy number loss that included the
BRCA1 gene on Chr 17 (Fig. 2). This region of DNA loss was physi-
cally followed by a distinct plateau of amplification at 17q21.3
extending toward the telomere (43M–46M, hg18), suggesting that
a common complex chromosomal configuration involving the en-
tire 17q armmay be part of the ERBB2 amplification process. When
we examined the breakpoints within this amplification-loss-ampli-
fication region on Chr 17q, in all three cases (BT47, BT55, and
BT146) the ERBB2 amplicon was directly connected to the 17q21.3
amplicon by large unpaired inversions (Fig. 2B). We also found such
coamplifications to be joined by an unpaired inversion in the
HCC2218 breast cancer cell line, which shares a similar 17q copy
number profile (Fig. 2B; Stephens et al. 2009), supporting the hy-
pothesis of a recurrent genomic mechanism among breast cancers.
To validate these observations, we systematically searched for
recurrent structural variations across the eight sequenced breast
cancers, seven of which show at least a minimal level of ERBB2
amplification. We defined recurrent structural variations as events
with >50% sequence overlap between the two breakpoint bound-
aries and whose breakpointsmappedwithin 3Mbp of one another
(Supplemental Methods). We found 45 loci with regionally re-
current rearrangements, corresponding to a total of 140 individual
rearrangements (Supplemental Table 7). Seventeen recurrent events
localize to Chr 17q, and at least six of them (comprising 38 in-
dividual structural variations and affecting six out of the eight
samples analyzed) appear to contribute to the characteristic 17q
genomic configuration described above (Supplemental Figs. 5, 7;
Supplemental Table 7).
Having observed a possible consistent mechanism of ERBB2
amplicon formation in this recurrent chromosomal rearrange-
ment, which involves BRCA1 loss and 17q21.3 coamplification, we
addressed the significance of such a configuration by interrogating
the copy number profile of a large number of breast cancer samples
accessible in publicly available databases (n = 1174) (Supplemental
Methods). We first classified all samples as ERBB2-amplified (log2
CN ratio > 1.0; n = 178) or nonamplified (log2 CN ratio < 1.0; n =
996).We then quantified the association between the ERBB2 status
and the copy number status of adjacent loci, BRCA1 and 17q21.3,
by comparing the frequencies of different combinations of copy
number patterns. As predicted, the frequencies of BRCA1 loss and
17q21.3 gain (calculated using the PHB gene as a surrogatemeasure
of the 17q21.3 amplicon) in ERBB2-amplified tumors were strik-
ingly higher than those in ERBB2 nonamplified samples (47%
versus 19% for BRCA1 loss, P-value = 4.134 3 1014; 54% versus
22% for 17q21.3 gain, P-value < 2.2 3 1016), indicating that
BRCA1 and 17q21.3 copy number changes are directly associated
with the magnitude of ERBB2 copy number (Supplemental Fig.
8A). Furthermore, we found that this specific configuration of
ERBB2-amplification/BRCA1-loss/17q21.3-gain occurs 4.25 times
more frequently than expected by chance (P-value < 1 3 107)
(Fig. 3). Focusing on samples that show an increase in the copy
number of both the ERBB2 and the 17q21.3 loci, we observed that
in cases in which the BRCA1 gene is also gained, the overall copy
number profile is indicative of 17q trisomy (median copy number
of 2.9 for ERBB2, BRCA1, and 17q21.3) (Supplemental Fig. 8B).
However, in cases where BRCA1 is copy number neutral or, even
more significantly, lost, ERBB2 and 17q21.3 gains have much
higher amplitudes (median copy number of 25.3 and 6.4 for ERBB2
and 17q21.3, respectively, in the presence of BRCA1 loss) (Sup-
plemental Fig. 8B). These data strongly suggest a physical dissoci-
ation of the BRCA1 gene from the two flanking loci in the early
events leading to their massive amplification.
We also noted that in seven out of the eight sequenced breast
cancer samples, regions of 17p, including the TP53 gene, appeared
as one copy; and in three samples,TP53 damaging pointmutations
affected the remaining allele (Supplemental Table 1). Remarkably,
copy number frequencies across a larger data set of 1174 breast
cancers (Supplemental Methods) showed that loss of TP53 was
more frequent in the ERBB2-amplified samples (58%) than in the
ERBB2-negative samples (41%, P-value = 1.777 3 105) (Supple-
mental Fig. 8A).Whenwe included TP53 copy number state in the
analysis of Chr 17 configurations in breast cancer, we found that the
loss of TP53 was significantly associated with the oncogenic 17q
copy number configuration as described above, increasing the
overall fold enrichment for this specific genomic pattern (i.e., TP53
loss, ERBB2 amplification, BRCA1 loss, and 17q21.3 gain) to 7.68-
fold greater than expected by chance (Fig. 3). These data altogether
suggest that there is a coordinated rearrangement involving the
Inaki et al.
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Figure 2. Oncogenic organization of Chr 17 in breast cancer. (A) Chromosomal map of Chr 17, showing copy number state of the eight breast tumors
analyzed, the frequency of copy number gain and loss across a combined data set of 1174 breast cancers, and the number of breast cancer prognosis-
associated genes per 40-gene windows. Clusters of poor and good prognosis associated genes are located in copy number gain and loss regions,
respectively. (B) Linear map of Chr 17, showing the frequency of copy number gain and loss as in A, as well as the copy number profile of three breast
tumors and a breast cancer cell line, HCC2218, with information on recurrent unpaired inversions (below).
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entire Chr 17, where significant segmental coamplification of
ERBB2 and genes on 17q21.3 occurs with the loss of the in-
tervening segment containing BRCA1, in conjunction with copy
number loss and disruptive mutations of TP53.
Mechanisms of the ERBB2 amplicon formation on Chr 17q
The resolution of mate-pair sequencing in defining and quantify-
ing structural variations provided a portal into the dynamics of
amplicon formation that enabled us to model, in detail, the
complex rearrangements on Chr 17q. In the breast tumor sample
BT55, the structural variations with the highest cluster sizes (N =
207–331) are an ;500-kbp tandem duplication harboring ERBB2
(TD207) and a recurrent unpaired inversion connecting the ERBB2
and the 17q21.3 amplicons (UI331) (Fig. 4). The breakpoints of the
two rearrangements coincide with a fivefold increase in the copy
number of both the ERBB2 and 17q21.3 loci. We speculate that the
tandem duplication, TD207, which causes an increase in ERBB2
copy number, occurred as the first event in the region and was
followed by an unpaired inversion, UI331, which physically con-
nects the ERBB2 and 17q21.3 amplicons (Fig. 4). A subsequent
deletion, Del51, caused the loss of a copy of the BRCA1 gene.
Similarly, in a detailed reconstruction of Chr 17q in BT146, three
tandem duplications (TD359, TD377, and TD426), all of which
include the ERBB2 locus, were followed by two unpaired inversions
(UI852 and UI626) connecting ERBB2with 17q21.3 and a deletion
(Del285) affecting BRCA1 (Supplemental Figs. 9A,B).
An analogous sequence of events characterizes ERBB2 amplifica-
tion inBT47 (Supplemental Fig. 9C),which shares a remarkably similar
copy number profile on Chr 17 with BT55 and BT146. Furthermore,
three samples with lower amplitude ERBB2 gains (BT58, BT71, and
BT73) also show evidence of at least some of these critical recurrent
17q rearrangements (Supplemental Fig. 5; Supplemental Table 7).
In both BT146 and BT73, we observed a second mechanism
leading to ERBB2 amplicon formation. In BT146, in addition to the
unpaired inversion generating a conjoint ERBB2-17q21.3 ampli-
con, the ERBB2 locus translocated to chromosome 16 and was
independently amplified (breakpoints: Inter591 and Inter826)
(Supplemental Fig. 9A). A reconstruction of the breakpoints sug-
gests the possibility that this alternative path of genomic ampli-
fication may have caused the ERBB2 gene to be embedded in an
episome structure (Supplemental Fig. 9B). In BT73, the ERBB2
amplicon appears to result from a series of interchromosomal
translocations between chromosomes 17 and 5, which follow an
initial tandem duplication event (Supplemental Fig. 9D). In this
setting, the ERBB2 gene physically disconnects from the down-
stream BRCA1 locus before being amplified in its new chromo-
somal location.
Taken together, this detailed structural variation mapping
revealed the presence of conserved mechanistic paths involved in
ERBB2 amplification. Although different rearrangements may
eventually be responsible for the final generation of the massive
copy number increase at the ERBB2 locus observed in ERBB2-
positive breast cancers, we were able to delineate a more general
sequence of events whereby an initial tandem duplication of the
ERBB2 locus is followed by specific rearrangements that physically
separate ERBB2 from BRCA1 favoring the subsequent massive
coamplification of the distal 17q21.3 region, thereby generating
a putatively optimal genomic configuration.
Functional consequences of 17q rearrangements in breast
cancer
Our results suggest that ERBB2 overexpression, BRCA1 loss, and
overexpression of genes on 17q21.3may represent an advantageous
expression configuration for breast cancer progression. We hypoth-
esized that these events would be at least additive in advancing the
cancer phenotype. To examine the combined biological effects of
ERBB2 overexpression and BRCA1 knockdown, we utilized non-
transformed human mammary epithelial cells (HMECs). Although
Figure 3. Enrichment of ERBB2-amplification, BRCA1-loss, PHB-gain, and TP53-loss in breast cancer (n = 1174 breast cancers). Fold enrichments correspond
to the ratio between observed and expected values, inwhich expected valueswere computed based on the individual frequencies of the four events examined
(ERBB2 amplification, BRCA1 loss, PHB gain, and TP53 loss). P-valueswere derived empirically from 10million shuffled data sets. (amp) Amplification (log2 copy
number ratio > 1.0); (gain) copy number gain (log2 copy number ratio > 0.3); (loss) copy number loss (log2 copy number ratio < 0.3).
Inaki et al.
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both ERBB2 overexpression and BRCA1 knockdown increased cell
proliferation in HMECs (P-value = 1.3 3 105 and P-value = 3.2 3
106, respectively), the combination of ERBB2 overexpression with
BRCA1 knockdown caused an increase in cell proliferation greater
than either perturbation individually (P-value = 3.73 102) (Fig. 5A;
Supplemental Fig. 10A). This supports the hypothesis that biological
selection would favor ERBB2-positive tumors that concurrently lose
the BRCA1 tumor suppressor gene.
Next, we aimed to identify driver oncogenes mapping to Chr
17q21.3. Because this locus appears to be a broad amplicon in
breast cancer, it is likely to harbor a cluster of oncogenes (Supple-
mental Fig. 11). The 17q21.3 amplified regions in BT55 and BT146
overlap and demarcate a region frequently amplified in breast
cancer (Supplemental Fig. 11). We selected candidate oncogenes
on 17q21.3 and assessed the effects of their targeted knockdownby
siRNAs on cell proliferation in 10 breast cancer cell lines, all of
which show copy number gain corresponding to the 17q21.3 re-
gion, with the exception of SKBR3. All the tested cell lines are
ERBB2-amplified, except MCF7 (Supplemental Table 8). Among
the 76 genes mapping to the 17q21.3 amplicon, 39 were expressed
(>1.5 FPKM) in both BT55 and BT146. We further narrowed down
this list to 21 genes, based on their association with breast cancer
patients’ poor prognosis (distant metastasis free survival and re-
lapse free survival) (Supplemental Methods), high expression in
cancer, and coexpression with the ERBB2 gene (Supplemental Ta-
ble 8; Methods). We first tested ERBB2 dependecies and found that
ERBB2 knockdown by siRNA induced a reduction in proliferation
in all ERBB2-amplified cell lines, exceptMB361 (Supplemental Fig.
12; Supplemental Table 9). We then applied siRNAs against the 21
17q21.3 gene candidates in all 10 cell lines and measured their
effect on cell proliferation. We found that a maximal effect was
achieved when ERBB2 was knocked down, and that the silencing
of 19 of the 21 candidate oncogenes also resulted in reduced
growth (Fig. 5B; Supplemental Table 9). Because siRNA effects
might bemore effective in highly amplified cell lines, we developed
a ‘‘copy number dependency’’ measure of the siRNA effects on cell
proliferation in each cell line:Wemultiplied the number of copies of
each tested gene by its corresponding siRNA-induced reduction in
cell proliferation (Supplemental Fig. 13A). As expected, the ERBB2
gene appeared to cause the strongest progrowth effect (score = 57).
The same 19/21 oncogene candidates on 17q21.3 also showed
growth associated potential, although to a lesser degree when
comparedwith ERBB2 (HOXB7 gene silencing generated the highest
score of 25.9) (Supplemental Fig. 13A), supporting the hypothesis
that a cluster of weak oncogenes maps to the broad peak region of
the 17q21.3 amplicon.
Synergistic effects of 17q21.3 oncogene silencing and ERBB2
inhibition
Next, we tested whether there may be interactive effects on cell
proliferation between ERBB2 and the 17q21.3 oncogenes, whose
genomic regions are physically connected and coamplified in
some breast cancers. To assess this question, we used Lapatinib,
an inhibitor of the ERBB2 and EGFR kinase activities that is ap-
proved for the treatment of patients with ERBB2-overexpressing
breast cancers (Arteaga et al. 2011). We treated each cell line with
Lapatinib at the appropriate IC50 concentration while silencing
each target gene on 17q21.3. Each one of the 19 siRNAs that caused
a decrease in cell proliferation when used individually caused
a further reduction in cell growth when applied in combination
with Lapatinib, suggesting that their targeted genes contribute
at minimum a cellular effect that is additive to the effect induced
by ERBB2 (Supplemental Table 9). Following an adjustment for
copy number effects across the cell lines (copy number depen-
dency) (Supplemental Fig. 13B), we computed the difference in the
Figure 4. Reconstruction of Chr 17q rearrangements in BT55. (A) Copy number and structural variations mapping to Chr 17 (17–63 Mb) in the BT55
sample. For each structural variation, the brown and pink arrowheads correspond to the left and rightmate-pair read clusters, respectively. SV breakpoints
map to the end of the brown arrowhead and to the start of the pink arrowhead (as detailed in Hillmer et al. 2011) and are indicated by dashed vertical lines.
(TD) Tandem duplication (yellow); (UI) unpaired inversion (red); (Del) deletion (green). The number associated with each structural variation corresponds
to its cluster size. (B) A schematic description of the plausible structural events that contributed to the final shape of Chr 17 in the BT55 cancer genome. An
initial tandem duplication (TD207) involving the ERBB2 locus was followed by unpaired inversions UI331 and UI75, which is in effect a TD on the cancer
genome, resulting in the joining of ERBB2 and the 17q21.3 locus. Subsequent events caused the loss of the BRCA1 locus and themassive coamplification of
the ERBB2 and 17q21.3 loci.
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reduction of cell proliferation for cells cultured in the presence or
in the absence of Lapatinib to measure the potential synergy or
antagonism between the inhibition of ERBB2 and the selected
17q21.3 genes (Fig. 5C). Seven of the 19 putative oncogenes
showed potential for synergismwith ERBB2, whereas three showed
plausible partial antagonism with ERBB2 in at least two cell lines
(Supplemental Table 10). When genes on chromosome 2p23,
whose frequency of copy number gain does not correlate with
ERBB2 amplification in breast cancer (10.9% in ERBB2-amplified
and 8.2% in ERBB2-nonamplified tumors based on the TCGA data
set), were tested for their synergy with ERBB2, we found signifi-
cantly fewer interactive genes compared to those on 17q21.3 (P =
1.91 3 107) (Supplemental Fig. 13C–E). Thus, genes in the
coamplified region of 17q21.3 appear to have discernible phar-
macological interactions with ERBB2 inhibition over randomly
selected genes.
One of the partially antagonistic genes, PDK2, was further
tested. The overexpression of PDK2 showed enhanced growth in
the native HMECs but not in ERBB2-overexpressing HMECs (Fig.
5D; Supplemental Fig. 10B). Thus, even though PDK2 is a growth
inductive gene, its effects are overshadowed by ERBB2 action,
suggesting that the growth promoting pathways elicited by PDK2
and ERBB2 are redundant. Similarly, althoughHOXB7 has a strong
isolated effect on growth individually, it appears to be antagonistic
to ERBB2-associated growth. Therefore, HOXB7 may have no
positive cancer evolutionary advantages upon coamplification
with ERBB2, even though it is a moderate progrowth gene when
acting alone. This appears to be correlated with a lower frequency
of copynumber gain ofHOXB7 thanothermembers of the 17q21.3
amplicon (Supplemental Fig. 11).
To generalize the portrayal of the 17q21.3 amplicon as an
oncogene cluster that contributes additive oncogenic potential to
a structurally connected locus, we asked if other broad amplicons
could be indicative of biologically relevant gene coamplifications.
By using the BT73 cancer genome as a model, we focused on the
generally broad amplicon on the telomeric end of the long arm of
Figure 5. Validation of the cancerous function of genes on Chr 17q. (A) Cell proliferation assay usingmock and ERBB2-overexpressing humanmammary
epithelial cells (HMECs), which were treated with shRNA against BRCA1 or a nontargeting shRNA. Knockdown of BRCA1 increases cell proliferation in both
conditions. The average of two independent experiments6 standard deviation is shown. P-values (Student’s t-test): (*) P-value = 3.73 102; (**) P-value =
1.3 3 105; (***) P-value = 3.2 3 106. (B) Cell proliferation assay for 10 breast cancer cell lines transfected with siRNAs against the 17q21.3 genes and
ERBB2. Each bar represents the sum of the reductions in cell proliferation caused by each individual siRNA across all cell lines examined. Gene symbols are
ordered based on chromosomal location (lower coordinates on left). (C ) Combined effect of Lapatinib treatment and cell transfection with siRNAs
targeting ERBB2, 17q21.3 genes, or 2p23 control genes in six breast cancer cell lines. The observed reduction in cell proliferation (CP) is multiplied by the
copy number (CN) in each cell line (copy number dependency) (Supplemental Fig. 13A,B). Bars correspond to the difference in cell proliferation reduction
between cells cultured in the presence and in the absence of Lapatinib. Positive values indicate putative synergistic effects between the Lapatinib and the
siRNA treatments, whereas negative values indicate antagonistic effects. Values close to zero represent cases in which the two treatments are independent.
A selection of genes mapping to the 2p23 control locus was made tomatch the range of gene expression levels observed for the 17q21.3 candidate genes
across the six experimental cell lines used in this experiment. (D) Cell proliferation assay using mock and ERBB2-overexpressing HMECs, which were
transfected with a PDK2-overexpressing vector or a negative control vector (NC), showing enhanced cell proliferation in mock HMECs following PDK2
overexpression (P-value = 3.193 103, Student’s t-test). The average of two independent experiments6 standard deviation is shown. qPCR data showing
changes in expression levels following gene silencing/overexpression are shown in Supplemental Figures 10 and 12.
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chromosome 8, which harbors the well-known MYC oncogene
(Supplemental Results; Supplemental Fig. 14). Searching for putative
oncogenes mapping to this region, we selected the serine/threonine
protein kinase-coding RIPK2 gene based on its association with poor
breast cancer patients’ outcome and on its statistically significant
coamplificationwithMYC (Supplemental Results). SiRNA-based gene
silencing confirmed that RIPK2 functions as a strong breast cancer
oncogene inMYC-amplified cancer cell lines (Supplemental Fig. 14).
Discussion
The maintenance of a full cancer phenotype is dependent on the
complement of genetic and epigenetic changes affecting genes
responsible for many cellular functions (Hanahan and Weinberg
2011). From whole-genome sequencing data, we learned that, al-
though there are some common oncogenic drivers, each cancer
shows combinations of genomic aberrations that often are unique
for that individual tumor. These structural aberrations and their
consequent expression profiles engage a range of biochemical and
cellular functions that, as a whole, cannot be ascribed to a single
oncogenic pathway. Using deep genomic analyses of breast cancers
to reveal the detailed genetic landscape of each tumor, we sought
to find coherence in how the many different somatic mutations
may be related.
By examining the detailed structural genomic alterations asso-
ciated with common amplicons, we found evidence for a sequence
of structural variations affecting recurrent regions of genomic am-
plification. In five of the sevenanalyzedbreast cancerswith evidence
of copy number gain at the ERBB2 locus, large tandem duplications
encompassing the ERBB2 gene appeared to initiate the amplification
of the region. Inmost cases, ERBB2 amplificationwas associatedwith
copynumber loss ofBRCA1 throughdifferent genomicmechanisms.
In three samples, unpaired inversions joined the ERBB2 locus with
the region on 17q21.3 that would be subsequently amplified; and in
all three cases, we found structural evidence for a deletion of the
intervening chromosomal segment containing the BRCA1 gene
(Supplemental Fig. 5). In the remaining samples, ERBB2 is amplified
through more complex rearrangements that included translocation
to other chromosomes and multiple unpaired inversions.
To extend this analysis to a larger data set, we analyzed a col-
lection of 1174 breast cancers and noted that despite the gene
order on 17q being ERBB2, BRCA1, followed by 17q21.3, among
the tumors with concomitant amplification of ERBB2 and of the
17q21.3 region, 81% (52/64 samples) showed either a decrease or
no increase in the copy number of the intervening BRCA1 locus.
This implies that in the vast majority of cases, BRCA1 is lost before
the ERBB2-17q21.3 linked region is amplified. In a different study,
60% of 200 ERBB2-amplified tumors show amplification of
17q21.3, whereas 40% show loss of the BRCA1 locus (Staaf et al.
2010). More recently, 2,000 breast tumors were divided into 10
subgroups based on their genomic and transcriptomic architecture
(Curtis et al. 2012). The ERBB2 subgroup (IntClust 5), consisting of
94 ERBB2-amplified tumors, showed coamplification of 17q21.3
and loss of BRCA1 in 36% and 54% of cases, respectively (Curtis
et al. 2012). Thus amplification of 17q21.3 and loss of BRCA1
represent a frequent configuration among ERBB2-amplified tumors.
Our detailed observations through deep sequencing for structural
variations in the eight breast cancers suggest that rearrangements,
such as unpaired inversions connecting the ERBB2 and 17q21.3 loci
or a direct deletion of BRCA1, followed by coamplification of the
newly linked ERBB2 and 17q21.3 loci, are among the key events
leading such an optimal genomic rearrangement.
If one views the genetic landscape of a tumor as an indication
of evolutionary optimization for any specific cancer, then the
identification of frequent conjoint genetic events can be a means
to discover additive or synergistic actions of oncogenic elements.We
validated this hypothesis in vitro by showing that overexpression of
ERBB2 and enforced knockdown of BRCA1 expression augmented
the growth of HMECs at a level greater than modulating each gene
alone. Recently, ERBB2 amplification and BRCA1 loss along with
MYC amplification were assessed to be early events before estab-
lishment of the ‘‘most-recent common ancestor’’ clone, which un-
dergoes subsequent expansion (Nik-Zainal et al. 2012). This is further
evidence that the gain of ERBB2 and the concomitant loss of BRCA1
are early events in breast tumor evolution andmay be advantageous
to breast cancer growth. Furthermore, the genomic configuration of
tumors harboring the ERBB2 amplicon also suggested that there is an
advantage for ERBB2 to be coamplified with genes residing on
17q21.3. We tested the biological role of 21 candidates on 17q21.3
using in vitro cell proliferation assays and found that 19 of the 21
genes exerted positive growth effects that were at least additive, and
in seven cases possibly synergistic with those elicited by ERBB2 ac-
tivity. Finally, the observation that TP53 copy number loss occurs in
79%of the cases inwhich BRCA1 is also lost (Fig. 3) strongly suggests
some functional interaction. Indeed, ithas beennoted thatTP53 and
BRCA1 interact together to optimally induce the expression of SFN
(14-3-3§), a major G2/M checkpoint control gene that blocks pro-
gression of cells withDNAdamage throughmitosis (Aprelikova et al.
2001). The loss of SFN regulationwould lead to abnormal checkpoint
control, a mechanism for genomic instability.
Thus, the chromosomal ‘‘origami’’ generated by the conjoint
rearrangements on 17q (ERBB2 tandem duplication followed by
unpaired inversions or deletions disrupting BRCA1 and linking
ERBB2 with the downstream 17q21.3 amplicon) appears to be a to-
pologically parsimonious strategy to generate a genomic state favor-
ing tumor growth (Fig. 6). In addition, through only a few genomic
rearrangements, the simultaneous activation by copy number gain
and the attenuation by copy number loss of genes affecting cancer
cell growth suggest that rearrangements significantly restructure the
cancer genome to engage the maximal number of oncogenic ele-
ments with each rearrangement, so that even small copy number
changes manifest to global changes in levels of gene expression.
It has been previously recognized that some cancer-associated
genes are colocalized in the genome. A classic example of this is the
overlapping localization of the p16INK4a and p14ARF tumor sup-
pressors encoded within the CDKN2A locus on 9p21. Deletions at
this locus routinely inactivate both cell-cycle regulators (Bates et al.
1998; Stott et al. 1998). Recent evidence also suggests that onco-
genes and tumor suppressor genes (TSGs) are clustered, including
several TSGs on 8p21-23 in hepatocellular carcinoma, three on-
cogenes (NKX2-1, NKX2-8, and PAX9) on 14q13 in lung cancer,
two oncogenes (CCND1 and FGF19) on 11q13, and two oncogenes
(BIRC2 and YAP1) on 11q22 in liver cancer (Zender et al. 2006;
Kendall et al. 2007; Sawey et al. 2011; Solimini et al. 2012; Xue et al.
2012). Similar to the results presented here, phenotypes induced
by the manipulation of individual genes are relatively weak,
whereas the concerted deregulation of entire cancer gene clusters
result in more significant effects. We found evidence that poor or
good breast cancer prognosis associated genes, which include
a significant number of oncogenes and TSGs, as well as markers of
cancerous elements (Zhang et al. 2009; Soon et al. 2011; Lee et al.
2012), cluster in regions of aberrant copy number and gene ex-
pression in breast cancer (Fig. 2; Supplemental Figs. 6A, 14A),
further supporting the hypothesis that clusters of cancer-relevant
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genes are distributed over the entire genome and are activated or
inactivated by copy number imbalances that contribute to the
oncogenic state.
Our results also suggest that the genomic configuration of a
breast cancer may identify conjointly expressed targets for combina-
tion therapy. One example is the coamplification of ERBB2 and
genes on the downstream 17q21.3 amplicon. The best possible targets
would be those that exhibit additive or synergistic effects with
Lapatinib treatment. Intriguing new candidates include SNF8, a
component of the endosomal sorting complex (ESCRT-II), which is
required for multivesicular body formation and involved in endo-
somal sorting (Malerød et al. 2007). The ESCRT-II complex is involved
in thedegradationofbothendocytosedEGFandEGFR.EME1, another
gene showing greater than additive effect with ERBB2, encodes a pro-
tein that is part of an endonuclease complex and may be involved in
DNA damage repair and maintaining genomic stability (Sengerova
et al. 2011). Other druggable candidate targets on 17q21.3 include
UBE2Z, an ubiquitin ligase, and KAT7 (previously known asMYST2),
a histone acetyltransferase, both of which showed an additive effect.
In summary, our work suggests that putative oncogenes
aggregate and separate from tumor suppressors in the human
genome. This clustering of oncogenic elements augments the
biological effect of segmental amplification and deletions com-
monly found in cancers as evidenced by their combined effects on
tumor growth in vitro. Therefore structural variations in breast
cancer act as systems organizers for gene cassettes that together
have a significant role in maintaining the cancer phenotype.
When viewed in evolutionary terms, the multitude of structural
rearrangements and mutations are not necessarily randomly de-
rived. Instead, it is a process of selection for the gain and loss of
adjacent clusters of gene cassettes that, when combined, optimize
tumor survivability and growth within a single individual. Given
that the combinatorics are immense, a systems analysis focusing
on multigene as opposed to single gene effects will be the best
approach in deciphering this level of complexity.
Methods
Breast tissue samples
After obtaining a patient’s written informed consent, breast tumor
tissues and peripheral blood samples were collected during surgery
at the Institute of Breast Diseases (FUCAM) in Mexico City. The
protocol was reviewed and approved by the Ethics and Research
committees of theNational Institute of GenomicMedicine and the
Institute of Breast Diseases in Mexico City (CE2009/11). After
macroscopic review by a trained pathologist, tumor tissues were
divided in half. One half was snap-frozen in liquid nitrogen and
kept at 80°C until further processing. The second half was fixed
in buffered formalin and embedded in paraffin. Tissue sections
were generated from this half and following hematoxilin-eosin
staining, they were independently reviewed by two pathologists.
Only tumors with >80% tumor cells were selected, and DNA and
RNA samples were isolated from their frozen tissue counterparts as
well as the corresponding peripheral blood lymphocytes, using the
AllPrep DNA/RNA mini kit (Qiagen).
Mate-pair DNA sequencing
Normal-tumor DNA paired samples from four breast cancer pa-
tients were processed and analyzed following the DNA paired-end
tag (DNA-PET) sequencing technology, as previously described
(BT55, BT73, BT122, and BT146) (Hillmer et al. 2011; Supple-
mental Table S1; Supplemental Methods), whereas another four
pairs were sequenced using the Illumina HiSeq 2500 platform,
following standard Nextera mate-pair library preparation (BT47,
BT58, BT71, and BT191) (Supplemental Table S1; Supplemental
Methods).
Mate-pair sequencing data for the 16 libraries were analyzed as
described in Hillmer et al. (2011). Briefly, mate-pair reads were sep-
arated into concordant and discordant ones, based on whether they
mapped back to the reference genome in the expected fashion or
not. Discordant mate-pair reads were then used to predict structural
Figure 6. Schematic overview of sequential rearrangements leading to the oncogenic configuration on 17q.
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variations, based on their relative orientation and mapping co-
ordinates. Overlapping discordant mate-pair reads were clustered
together as they represent the same rearrangement. The number of
mate-pair reads clustering together and pointing to the same
structural variation was represented by the cluster size.
For each pair of normal and tumor libraries, discordant mate-
pair read clusters were compared to search for significant overlaps
(i.e., any overlap within a distance equivalent to the maximum
library size from each end of any given cluster in both directions).
Only clusters specific for the tumor library were considered to be
indicative of somatic rearrangements and used as the input for
structural variation classification, as described in Hillmer et al.
(2011). Circos plots summarizing all the somatic structural varia-
tions in each cancer genome were generated using the Circos
software (Krzywinski et al. 2009).
Selection of 17q21.3 oncogene candidates
We first identified the 76 genes mapping to the 17q21.3 amplified
genomic region in BT55 and/or BT146. Of these, 39 genes were
selected based on a level of gene expressions (RNA-seq) higher than
1.5 FPKM in both BT55 and BT146. We then scored the following
parameters for the selection of the final list of 21 candidate
oncogenes: (1) significant gene overexpression in ductal breast
carcinoma compared with normal tissue (P-value < 0.05, fold
change > 1.5, based on Oncomine data sets [http://www.oncomine.
org/]); (2) significant negative correlation of gene expression with
breast cancer patients’ relapse free survival (P-value < 0.05, n = 2422,
based on the KM plotter database [http://kmplot.com/analysis/]);
(3) mapping to significant amplicon peaks, as defined based on the
Tumorscape data portal (http://www.broadinstitute.org/tumorscape/,
breast cancer data set, n = 240), frequent amplicon regions in ERBB2-
amplified breast cancers (Staaf et al. 2010) (n = 200), and gene ex-
pression amplicons defined by the local singular value decomposition
(Zhang et al. 2009); (4) significant positive correlation with ERBB2
gene expression (P-value < 0.05), based on six independent
microarray data sets (van de Vijver et al. 2002; Miller et al. 2005;
Pawitan et al. 2005; Wang et al. 2005; Ivshina et al. 2006; Loi et al.
2007); and (5) negative gene expression correlation with distant
metastasis free survival (DMFS) based on the union of the six ex-
pression data sets described in parameter (4).
Gene expression estimate values for the six breast cancer
microarray studies indicated in (4) above were obtained by ap-
plying the MAS5.0 global mean method to Affymetrix CEL files
downloaded from the Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo/). Probe set-based signal intensities
were log-transformed and scaled by adjusting the mean intensity
to a target signal value of log(500). To remove cohort-dependent
array biases, arrays within each cohort weremedian-centered prior
to combining them into one data set. Meta-analysis on the asso-
ciation of candidate gene expression with DMFS was performed
using Partek Genomics Suite. The ERBB2 status was determined by
splitting samples by the median expression of ERBB2 in each in-
dividual cohort.
Cell lines
Breast cancer cell lines were obtained from the ATCC. Cells were
cultured in RPMI or DMEM supplemented with 10% FBS and
maintained at 37°C and 5% CO2. Details of the growth medium
and Lapatinib concentration used for the in vitro experiments are as
follows: HCC202 (RPMI, 130nM); UACC893 (DMEM, 300nM);
HCC1419 (RPMI, 70nM); HCC2218 (RPMI, 40nM); ZR75-30 (RPMI,
35nM); BT474 (RPMI, 70nM); SKBR3 (DMEM, 40nM); MB361
(DMEM); MCF7 (DMEM); and CAMA1 (DMEM). Immortalized
human mammary epithelial cells (HMECs), stably transfected with
empty vector or ERBB2, were established in the Yu Qiang laboratory
(GIS, Singapore). HMECs were cultured in DMEM/F12 (Invitrogen)
with 5%horse serum, 50 ng/mL EGF, 500 ng/mL hydrocortisone, 10
mg/mL insulin, 100 ng/mL cholera toxin, and 100 units/mL peni-
cillin, maintained at 37°C with 5% CO2.
Copy number data for the cell lines were obtained from a pre-
vious study (Kao et al. 2009) and smoothened using the DNAcopy
package in R (Venkatraman andOlshen 2007), exceptCAMA1,whose
copy number profile was obtained from the Tumorscape database.
Gene knockdown and cell proliferation assay
For the siRNA experiments using breast cancer cell lines, cells were
plated at day 0 in 12-well plates, in triplicate, and at an appropriate
cell density to assure that they would be in the log phase of cell
growth at the time of the assay (2–63 104 cells/mL). On day 1, cells
were transfectedwith 20 or 40 pmol of ON-TARGET plus SMARTpool
siRNA (Dharmacon) using Lipofectamine 2000 and Opti-MEM
(Invitrogen) according to the manufacturer’s instructions. In ex-
periments testing the effect of Lapatinib, the drug (purchased from
LC Laboratories) was added to the culture at the cell line-specific
IC50 concentration on day 2. Cell proliferation was assessed on
day 6 using Cell Counting Kit-8 (Dojindo). Cells transfected with
a nontargeting siRNA were used as a negative control (NC).
HMECswere transfectedwith plasmid-based shRNAs (BRCA1:
ggagatcaagaattgttacaa; negative control: ggaatctcattcgatgcatac;
Qiagen, 336312 KH00322H) using Lipofectamine 2000. Forty-
eight hours after transfection, the cells were replated and stably
selected with 250 mg/mL of hygromycin (Merck Calbiochem). For
the proliferation assay, cells were plated in quadruplicate in 96-well
plates, at a density of 2500 cells/well. Cell proliferation was mea-
sured after 48 h using WST-1 (Roche).
PDK2 stable overexpression
pEB Multi-Neo vector (Wako), in which genes encoding PDK2
with a C terminus HA tag and IRES-DsRed-express2 (Clontech)
were inserted, was transfected into HMECs using Lipofectamine
2000. The pool of transfected cells was passaged once before
a double sorting of DsRed-expressing cells via fluorescence acti-
vated cell sorting. The sorted cells were passaged once before pro-
ceeding to the WST-1 proliferation assay. A pEB Multi-Neo vector
with IRES-DsRed-express2 was used as the negative control vector.
Additional methods
Additionalmethods for RNA-seq, DNA-PET, andNexteramate-pair
library preparation and sequencing as well as source details for the
publicly available data sets utilized in this study are provided in the
Supplemental Methods.
Data access
Raw sequencing and processed RNA-seq data from this study
have been submitted to the NCBI Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number
GSE57914.Whole-genome sequencing data have been submitted
to the NCBI Sequence Read Archive (SRA; http://www.ncbi.
nlm.nih.gov/sra) under accession numbers PRJNA253369 and
PRJNA251354.
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